Endoscopic balloon dilatation for the treatment of primary obstructive megaureter <24 months of age: Does the size of the balloon influence results?

Balloon catheter Endoscopic balloon dilatation Hydroureteronephrosis Primary obstructive megaureter Ureteral obstruction

Journal

Journal of pediatric urology
ISSN: 1873-4898
Titre abrégé: J Pediatr Urol
Pays: England
ID NLM: 101233150

Informations de publication

Date de publication:
04 2023
Historique:
received: 08 07 2022
revised: 17 11 2022
accepted: 20 11 2022
medline: 28 3 2023
pubmed: 10 12 2022
entrez: 9 12 2022
Statut: ppublish

Résumé

Endoscopic balloon dilatation (EBD) can be performed with different catheters and its durability is still controversial. This study aimed to compare long-term results of EBD performed <24 months of age using balloons of 4 mm vs. 6 mm in diameter. Retrospective study of consecutive patients with unilateral primary obstructive megaureter (POM) undergoing EBD <24 months of age by two surgeons from 01/2009 to 12/2020. The technique was consistent, but for balloon diameter, which was 4 mm in group A vs. 6 mm in group B. End-points included peri-operative complications, success rate (improving dilatation and non-obstructive drainage on 9-month scintigraphy), and long-term outcome (need for reimplantation and diameter of retrovesical ureter at last ultrasound). The procedure was completed in all planned patient. Group A included 15 patients and Group B 30 patients. Groups were not significantly different for age (p < 0.09), gender (p < 0.1), laterality (p < 0.7), and preoperative median ureteral diameter (p = 0.08). No perioperative complications occurred. Four group A patients required a cutting balloon to achieve a satisfactory dilatation of the vesicoureteral junction (p = 0.009). After a median (range) follow-up of 70 (19-155) months, success rate was 73.3% vs. 83.3% (p = 0.45), 4/15 group A and 5/30 group B patients required reimplantation within 2 years of EBD. In successful cases, median (range) ureteral diameter at last follow-up was 6 (0-17) mm vs. 5 (0-14) mm, which was significantly better than preoperative value (p = 0.003 and p < 0.001, respectively), but not significantly different (p = 0.8) between groups. EBD is an umbrella term that encompasses many technical variations, which can be key for success. Although limited by the small numbers and the comparison of patients treated over two subsequent periods, this is the first study focusing on the role of balloon size. The diameter of the balloon did not influence significantly long-term results, but the 6 mm balloon slightly increased the success rate of EBD to 83.3% and eliminated the need for cutting balloons to achieve a satisfactory dilatation.

Identifiants

pubmed: 36494270
pii: S1477-5131(22)00536-8
doi: 10.1016/j.jpurol.2022.11.021
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

198.e1-198.e9

Informations de copyright

Copyright © 2022 Journal of Pediatric Urology Company. Published by Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

conficts of interest None.

Auteurs

Giorgia Contini (G)

Pediatric Urology Unit, Bambino Gesù Children's Hospital and Research Centre, Piazza S. Onofrio 4, 00165, Rome, Italy.

Ermelinda Mele (E)

Pediatric Urology Unit, Bambino Gesù Children's Hospital and Research Centre, Piazza S. Onofrio 4, 00165, Rome, Italy.

Nicola Capozza (N)

Pediatric Urology Unit, Bambino Gesù Children's Hospital and Research Centre, Piazza S. Onofrio 4, 00165, Rome, Italy.

Marco Castagnetti (M)

Pediatric Urology Unit, Bambino Gesù Children's Hospital and Research Centre, Piazza S. Onofrio 4, 00165, Rome, Italy; Department of Surgery, Oncology, and Gastroenterology, University of Padova, Padua, Italy. Electronic address: marco.castagnetti@opbg.net.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH